Postmenopausal women on adjuvant letrozole for early breast cancer face accelerated bone loss from estrogen suppression. This phase III RCT randomized 1065 women to immediate zoledronic acid versus delayed dosing triggered by fracture or BMD decline. The primary endpoint was lumbar spine BMD change, with disease-free and overall survival as secondary endpoints.
When you start a postmenopausal breast cancer patient on an aromatase inhibitor, you have committed her to accelerated bone loss. Estrogen maintains bone, and letrozole drives estrogen to undetectable levels. This trial answers whether to give zoledronic acid upfront or wait. Immediate dosing preserved bone (+4.3% vs −5.4% lumbar BMD) and, unexpectedly, reduced disease recurrence by 34%.
The mechanistic signal matters: benefit was largest in women deep into menopause, supporting the idea that bisphosphonates act on dormant tumor cells in a low-estrogen environment. This mirrors the AZURE and ABCSG-12 postmenopausal subsets.
Weight the evidence appropriately. This was Novartis-sponsored and open-label, overall survival did not reach significance, and the delayed arm was contaminated by crossover. The DFS finding remains debated and should not be read as definitive.
Postmenopausal women on adjuvant letrozole for early breast cancer face accelerated bone loss from estrogen suppression. This phase III RCT randomized 1065 women to immediate zoledronic acid versus delayed dosing triggered by fracture or BMD decline. The primary endpoint was lumbar spine BMD change, with disease-free and overall survival as secondary endpoints.
When you start a postmenopausal breast cancer patient on an aromatase inhibitor, you have committed her to accelerated bone loss. Estrogen maintains bone, and letrozole drives estrogen to undetectable levels. This trial answers whether to give zoledronic acid upfront or wait. Immediate dosing preserved bone (+4.3% vs −5.4% lumbar BMD) and, unexpectedly, reduced disease recurrence by 34%.
The mechanistic signal matters: benefit was largest in women deep into menopause, supporting the idea that bisphosphonates act on dormant tumor cells in a low-estrogen environment. This mirrors the AZURE and ABCSG-12 postmenopausal subsets.
Weight the evidence appropriately. This was Novartis-sponsored and open-label, overall survival did not reach significance, and the delayed arm was contaminated by crossover. The DFS finding remains debated and should not be read as definitive.